FRLN News and Press, Freeline Therapeutics Holdings plc From 01/04/21

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of ...

Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with the U.S. FDA with expected initiation of pivotal Phase 2b/3 trial p...

LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of ...

LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of ...

- U pdated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes - Potentially increasing safety and efficacy in Freeline’s AAV delivery model LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Freeline Th...

Freeline Therapeutics (FRLN): 1H Net loss of $33.26M.Cash and cash equivalents of $252.64M at Sept. 30.Press Release For further details see: Freeline Therapeutics reports 1H results

Will report u pdated durability data from Phase 1/2 B-AMAZE trial in H aemophilia B in Q4 Th ird wholly-owned program me expected to be in the clinic in 2021 Strong cash position with over $250 million at 30...

Strong need for improved enzyme replacement therapies. Protalix's deliberately engineered ERT appears to fill this unmet need. Significant potential for share price appreciation. For further details see: Protalix Could Claim Substantial Global Market Share In Fabry Disea...

LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of...

LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives o...